Oxford, U.K.-based Sensyne Health plans to bring its artificial intelligence tools to America, and it’s enlisting IT services giant Cognizant and data infrastructure specialist Agorai to help do it.
The digital health products making the jump will include GDm-Health, therapeutic software prescribed to help manage gestational diabetes; EDGE, a program for monitoring chronic obstructive pulmonary disorder at home; and Support-HF, to track daily vital signs at home following heart failure.
In the U.K., Sensyne also maintains the air pollution monitoring program CleanSpace, and SEND, an early warning system and vital-sign recording platform designed for hospitals.
GDm-Health, currently used in 15 National Health System (NHS) trusts and by about 6,100 patients, will be the first of the group to make its U.S. debut. No U.K. patient data will be shared through the agreements, the company said. The products were first developed within the NHS, in collaboration with the University of Oxford before being licensed to Sensyne.
RELATED: Bayer teams up with AI firm Sensyne Health to mine NHS data for its heart disease pipeline
“Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the U.K.’s NHS, is realised in the U.S. market,” said Lord Paul Drayson, CEO of Sensyne.
“Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to U.S. health care providers and the commercial return made by Sensyne will be shared with the NHS.”
RELATED: AI data miner Sensyne Health looks to go public with $77M listing
This year, Sensyne partnered up with Bayer to mine anonymized patient data from the NHS to help design trials and develop treatments for cardiovascular disease. This includes genomic sequencing data and real-world evidence.
In the deal, Sensyne describes itself as a “docking station” that oversees the flow of data and insights between the NHS and commercial interests, keeping protected patient information from being sold or transferred to a third party.
A few months later, Bayer spun its AI collaboration with Sensyne into a full-fledged project among its international LifeHubs, which includes innovation centers in France, Germany, the U.S., Singapore and Japan.